Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | February 01, 2018 | February 05, 2018 |
| Medpace Holdings, Inc.MEDP · Entity 3327 | Director · President & CEO · 10% owner | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 20,000 |
Reported balance
After 2018-02-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-01 · Grant · Acquired 20,000 · Balance 20,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 29,994 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 29,994 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 1,642,492 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,642,492 F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 268,428 |
Reported balance
Holding disclosure · report date 2018-02-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 268,428 F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
F2: The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.
F3: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Medpace Holdings, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 338,225 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Sale · Disposed 26,701 · Balance 360,191 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. Row 2 · 2026-09-30 · Sale · Disposed 21,966 · Balance 338,225 F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy Medpace Investors, LLC | 4,733,019 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,733,019 F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.35. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.105 to $628.08. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 12, 2023 20:32 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 49,347 | $220.85 | $10,898,284.95 |
DisclosureSEC source: 0000892251-23-000071 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,233,019 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on February 20, 2023. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $220.00 to $222.585. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 110,324 | $223.05 | $24,607,768.20 |
DisclosureSEC source: 0000892251-23-000069 · form4.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,282,366 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on February 20, 2023. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $220.00 to $226.26. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 58,681 | $220.46 | $12,936,813.26 |
DisclosureSEC source: 0000892251-23-000069 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,392,690 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on February 20, 2023. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $220.00 to $221.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:24 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 31,648 | $221.83 | $7,020,475.84 |
DisclosureSEC source: 0000892251-23-000046 · form4.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,451,371 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on February 20, 2023. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $220.00 to $230.94. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:46 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantRestricted Stock Unit · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003510 · doc1.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MEDP common stock. F3 · derivative.exercise_date: The restricted stock units vest in full on the fourth anniversary of the grant date or February 17, 2027, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. F3 · derivative.expiration_date: The restricted stock units vest in full on the fourth anniversary of the grant date or February 17, 2027, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. Read SEC document |
| September 22, 2022 Filed Sep 23, 2022 20:01 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 57,426 | $154.59 | $8,877,485.34 |
DisclosureSEC source: 0001567619-22-017772 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,483,019 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $152.49 to $156.06. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 94,119 | $161.63 | $15,212,453.97 |
DisclosureSEC source: 0001567619-22-017725 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,425,593 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $157.83 to $163.71. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:13 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 94,119 | $155.14 | $14,601,621.66 |
DisclosureSEC source: 0001567619-22-017725 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,331,474 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $151.72 to $157.02. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 94,119 | $153.48 | $14,445,384.12 |
DisclosureSEC source: 0001567619-22-017630 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,237,355 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.50 to $155.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 62,516 | $149.58 | $9,351,143.28 |
DisclosureSEC source: 0001567619-22-017630 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,143,236 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $147.35 to $151.65. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 20:09 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 62,516 | $153.11 | $9,571,824.76 |
DisclosureSEC source: 0001567619-22-017541 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,080,720 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.94 to $155.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:09 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 62,516 | $152.66 | $9,543,692.56 |
DisclosureSEC source: 0001567619-22-017541 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 6,018,204 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.49 to $155.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 62,516 | $157.12 | $9,822,513.92 |
DisclosureSEC source: 0001567619-22-017415 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,955,688 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $153.65 to $163.66. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 20:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 62,515 | $167.58 | $10,476,263.70 |
DisclosureSEC source: 0001567619-22-017415 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,893,172 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $163.95 to $168.93. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 56,557 | $164.33 | $9,294,011.81 |
DisclosureSEC source: 0001567619-22-017265 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,830,657 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $159.77 to $166.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:15 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 56,557 | $157.65 | $8,916,211.05 |
DisclosureSEC source: 0001567619-22-017265 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,774,100 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.98 to $159.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 56,557 | $150.72 | $8,524,271.04 |
DisclosureSEC source: 0001567619-22-017170 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,717,543 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $145.30 to $154.52. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:10 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 56,557 | $147.59 | $8,347,247.63 |
DisclosureSEC source: 0001567619-22-017170 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,660,986 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.76 to $149.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 48,714 | $144.98 | $7,062,555.72 |
DisclosureSEC source: 0001567619-22-017048 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,604,429 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022. F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.70 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 42,076 | $144.52 | $6,080,823.52 |
DisclosureSEC source: 0001567619-22-017048 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,555,715 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $143.20 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:02 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 8,330 | $145.00 | $1,207,850.00 |
DisclosureSEC source: 0001567619-22-014239 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,513,639 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.885 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 20:06 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | PurchaseCommon Stock | 22,290 | $144.59 | $3,222,911.10 |
DisclosureSEC source: 0001567619-22-014112 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,505,309 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022. F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $142.97 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $90.65 | $0.00 |
DisclosureSEC source: 0001567619-22-006231 · doc1.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2024-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested on August 5, 2019. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:21 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | Exercise / conversionCommon Stock | 100,000 | $90.65 | $9,065,000.00 |
DisclosureSEC source: 0001567619-22-006231 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:11 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | GrantEmployee Stock Option (Right to Buy) · Derivative | 93,174 | $0.00 Strike: $138.87 | $0.00 |
DisclosureSEC source: 0001567619-22-004860 · doc1.xml · derivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,174 Underlying: Common Stock · 93,174 shares Expires 2029-08-15 F2 · derivative.exercise_date: The option vests on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:18 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 3,338 | $213.44 | $712,462.72 |
DisclosureSEC source: 0001567619-22-000730 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,483,019 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $216.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 19,744 | $212.70 | $4,199,548.80 |
DisclosureSEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 3 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,486,357 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $217.36. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 13,069 | $219.14 | $2,863,940.66 |
DisclosureSEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,506,101 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.48 to $220.44. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 17,376 | $220.34 | $3,828,627.84 |
DisclosureSEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,519,170 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.835 to $222.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 19:45 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 16,750 | $220.16 | $3,687,680.00 |
DisclosureSEC source: 0001567619-21-022666 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,536,546 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.635 to $221.125. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 19:45 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 24,118 | $222.18 | $5,358,537.24 |
DisclosureSEC source: 0001567619-21-022666 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,553,296 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.395 to $229.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 39,171 | $226.11 | $8,856,954.81 |
DisclosureSEC source: 0001567619-21-022564 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,577,414 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $223.28 to $227.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 22,830 | $223.19 | $5,095,427.70 |
DisclosureSEC source: 0001567619-21-022564 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,616,585 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $219.94 to $224.68. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 19:46 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 38,960 | $220.50 | $8,590,680.00 |
DisclosureSEC source: 0001567619-21-022495 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,639,415 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.08 to $222.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 19:46 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 18,133 | $215.17 | $3,901,677.61 |
DisclosureSEC source: 0001567619-21-022495 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,678,375 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.785 to $217.53. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:44 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 22,734 | $212.57 | $4,832,566.38 |
DisclosureSEC source: 0001567619-21-022408 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,696,508 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.12. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:44 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 30,605 | $213.59 | $6,536,921.95 |
DisclosureSEC source: 0001567619-21-022408 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,719,242 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 5,959 | $210.22 | $1,252,700.98 |
DisclosureSEC source: 0001567619-21-022252 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,749,847 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 2,424 | $210.28 | $509,718.72 |
DisclosureSEC source: 0001567619-21-022252 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,755,806 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.5425. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 309 | $210.20 | $64,951.80 |
DisclosureSEC source: 0001567619-21-021935 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,758,230 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 14,994 | $212.13 | $3,180,677.22 |
DisclosureSEC source: 0001567619-21-021935 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,758,539 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.455. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,871 | $212.89 | $3,378,777.19 |
DisclosureSEC source: 0001567619-21-021832 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,773,533 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.46. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:17 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 18,520 | $211.78 | $3,922,165.60 |
DisclosureSEC source: 0001567619-21-021832 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,789,404 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:16 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 400 | $211.48 | $84,592.00 |
DisclosureSEC source: 0001567619-21-021704 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,807,924 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $211.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 21:06 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 6,090 | $210.79 | $1,283,711.10 |
DisclosureSEC source: 0001567619-21-021582 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,808,324 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:06 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 26,642 | $211.57 | $5,636,647.94 |
DisclosureSEC source: 0001567619-21-021582 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,814,414 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 197 | $210.29 | $41,427.13 |
DisclosureSEC source: 0001567619-21-021383 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,841,056 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 12,115 | $212.10 | $2,569,591.50 |
DisclosureSEC source: 0001567619-21-021383 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,841,253 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.345. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 15,071 | $210.99 | $3,179,830.29 |
DisclosureSEC source: 0001567619-21-021226 · doc1.xml · nonDerivative · entry 2 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,853,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:23 UTC | Medpace Holdings, Inc. MEDP · Entity 3327 | SaleCommon Stock | 14,578 | $213.26 | $3,108,904.28 |
DisclosureSEC source: 0001567619-21-021226 · doc1.xml · nonDerivative · entry 1 Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Medpace Investors, LLC Disclosed balance after: 5,868,439 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $214.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.